CD274 and breast carcinoma: Present breast cancer treatment have hit a plateau; novel therapeutic strategies are sought [3].In 2019, the U.S. Food and Drug Administration initially authorized the anti-programmed cell death ligand 1 (PD-L1) inhibitor Atezolizumab for the first-line management of PD-L1-positive advanced triple-negative breast cancer, marking a new adventure in immunotherapy for breast cancer [4].